@article{fdi:010075486,
  title = {{H}erbal medicine for epilepsy seizures in {A}sia, {A}frica and {L}atin {A}merica : a systematic review},
  author = {{A}uditeau, {E}. and {C}hassagne, {F}. and {B}ourdy, {G}enevi{\`e}ve and {B}ounlu, {M}. and {J}ost, {J}. and {L}una, {J}. and {R}atsimbazafy, {V}. and {P}reux, {P}. {M}. and {B}oumediene, {F}.},
  editor = {},
  language = {{ENG}},
  abstract = {{R}elevance: {M}ore than 70 million people suffer epilepsy worldwide. {L}ow availability of anti-epileptic drugs, side effects and drug-resistant epilepsy affect the quality of life of persons with epilepsy in countries with a poorly developed health system. {H}erbal medicine is frequently used for this neurological condition. {O}bjectives: {T}he main objective was to provide a detailed analysis of {H}erbal {M}edicine used for neurological conditions related with epilepsy in {A}sia, {A}frica and {L}atin {A}merica. {M}ore broadly, this study aims to highlight species with assessed efficacy (cross-cultural use, pharmacological effects on models of epileptic seizures) and safety (toxicological data in laboratory) information, in order to point out species of interest for further studies. {A} critical assessment of models used in pharmacological evaluations was done. {M}aterials and methods: {T}he systematic search for {H}erbal {M}edicine treatments for epilepsy was performed considering all the articles published until {F}ebruary 2017 through three scientific databases. {I}t was made with {M}e{SH} terms and free text defining the epilepsy seizures and plant species. {W}e included studies carried out in {A}sia, {A}frica and {L}atin {A}merica. {A}ll articles reporting the use of {H}erbal {M}edicine to treat epilepsy seizures and/or their pharmacological evaluation were retained for further analysis. {R}esults: {T}he search yielded 1886 articles, from 30 countries. {H}undred and six articles published between 1982 and 2017 were included, corresponding to a total of 497 use reports for 351 plant species belonging to 106 families. {T}hree hundred and seventy seven use reports corresponding to 264 species in ethnopharmacological surveys and 120 evaluation reports corresponding to 107 species were noted. {T}wenty-nine reports, for 29 species, combined both ethnopharmacological and pharmacological evaluation. {F}ifty eight studies originated from {A}frica, 35 studies from {A}sia and 18 from {L}atin {A}merica. {H}ighest use report was noted for rhizomes of {A}corus calamus {L}. (12 use report in 1 country) and leaves of {B}acopa monnieri ({L}.) {W}ettst. (8 use report in 2 countries). {T}herefore these species display the highest use convergence. {R}egarding pharmacological evaluation most studied species were: {L}eonotis leonurus ({L}.) {R}.{B}r. (4 evaluation reports in 1 country), {U}ncaria rhynchophylla ({M}iq.) {M}iq. ex {H}avil. (3 evaluation reports in 2 countries) and {C}alotropis gigantea ({L}.) {D}ryand. (3 evaluation reports in 1 country). {I}n vivo models of chronic epilepsy were more relevant than in vitro models or chemical models inducing acute seizures for pharmacological assessment. {C}onclusion: {S}pecies with the highest use report were not those with pharmacological evaluation. {I}t will be pertinent to assess the pharmacological effects and safety of medicinal plants used mostly by traditional healers on predictive models of seizures.},
  keywords = {{E}pilepsy ; {S}eizure ; {H}erbal medicine ; {M}edicinal plant ; {A}sia ; {L}atin {A}merica ; {A}frica ; {P}harmacological models ; {ASIE} ; {AFRIQUE} ; {AMERIQUE} {LATINE}},
  booktitle = {},
  journal = {{J}ournal of {E}thnopharmacology},
  volume = {234},
  numero = {},
  pages = {119--153},
  ISSN = {0378-8741},
  year = {2019},
  DOI = {10.1016/j.jep.2018.12.049},
  URL = {https://www.documentation.ird.fr/hor/fdi:010075486},
}